Plasmodium sporozoite NPDP peptides as vaccine and target novel malaria vaccines and antibodies binding to

Patent metadata

Field	Value
Publication number	US-12383609-B2
Application number	US-201816606207-A
Country	US
Kind code	B2
Filing date	Apr 19, 2018
Priority date	Apr 19, 2017
Publication date	Aug 12, 2025
Grant date	Aug 12, 2025

Abstract

The present invention provides a fragment of plasmodium circumsporozoite protein according to SEQ ID NO: 1, for example for use in a malaria vaccine. The present invention also provides nucleic acids encoding a fragment of plasmodium circumsporozoite protein according to SEQ ID NO: 1, compositions comprising a fragment of plasmodium circumsporozoite protein according to SEQ ID NO: 1 and antibodies binding to a fragment of plasmodium circumsporozoite protein according to SEQ ID NO: 1. The antibodies according to the present invention bind specifically to P. falciparum sporozoites and may be used in the treatment and/or prevention of malaria.

First claim

The invention claimed is:

1. A recombinant nucleic acid molecule comprising:
(i) a polynucleotide encoding an antibody, or an antigen-binding fragment thereof, that is capable of binding to a Plasmodium falciparum sporozoite, wherein the antibody, or the antigen-binding fragment thereof, comprises:
a heavy chain variable region (VH) comprising a CDRH1, a CDRH2, and a CDRH3, the heavy chain variable region (VH) having an amino acid sequence, the amino acid sequence consisting of SEQ ID NO: 248;
a light chain variable region (VL) comprising a CDRL1, a CDRL2, and a CDRL3, the light chain variable region (VL) having an amino acid sequence, the amino acid sequence consisting of SEQ ID NO: 249;
an IgG1 Fc moiety comprising:
a heavy chain amino acid sequence, wherein the heavy chain amino acid sequence is according to SEQ ID NO: 313; and
a light chain amino acid sequence, wherein the light chain amino acid sequence is according to SEQ ID NO: 314 or 315; and

(ii) a promoter sequence.

2. A vector comprising the recombinant nucleic acid molecule according to claim 1 .

3. The vector of claim 2 , which is an expression vector, a cloning vector, or a transfer vector.

4. A cell comprising a vector according to claim 2 .

5. The cell according to claim 4 , wherein the cell comprises a eukaryotic cell.

6. The cell according to claim 5 , wherein the cell comprises a CHO cell, a NS0 cell, a PER.C6 cell, a HEK293T cell, a HKB-11 cell, a myeloma cell, a hybridoma cell, a yeast cell, a plant cell, a human liver cell, a human B cell, or a human plasma cell.

7. A pharmaceutical composition comprising:
a recombinant nucleic acid molecule according to claim 1 , and a pharmaceutically acceptable excipient, diluent, or carrier.

8. The recombinant nucleic acid molecule according to claim 1 , comprising mRNA.

9. The recombinant nucleic acid molecule of claim 1 , in which the recombinant nucleic acid molecule is codon-optimized for expression in a CHO cell, a NS0 cell, a PER.C6 cell, a HEK293T cell, a HKB-11 cell, a myeloma cell, a hybridoma cell, a yeast cell, a plant cell, a human liver cell, a human B cell, or a human plasma cell.

10. The recombinant nucleic acid of claim 1 , wherein the light chain amino acid sequence of the IgG1 Fc moiety is according to SEQ ID NO: 314.

11. The recombinant nucleic acid of claim 1 , wherein the light chain amino acid sequence of the IgG1 Fc moiety is according to SEQ ID NO: 315.

12. The recombinant nucleic acid molecule according to claim 1 , wherein the polynucleotide comprises a sequence consisting of SEQ ID NO: 256.

13. The recombinant nucleic acid molecule according to claim 1 , wherein the polynucleotide comprises a sequence consisting of SEQ ID NO: 257.

14. The recombinant nucleic acid molecule according to claim 1 , wherein polynucleotide comprises a sequence consisting of SEQ ID NO: 256 and a sequence consisting of SEQ ID NO: 257.

15. The recombinant nucleic acid molecule according to claim 1 , wherein the polynucleotide comprises a sequence consisting of SEQ ID NO: 316.

16. The recombinant nucleic acid molecule according to claim 1 , wherein the polynucleotide comprises a sequence consisting of SEQ ID NO: 318 that encodes the light chain amino acid sequence of the IgG1 Fc moiety.

17. The recombinant nucleic acid molecule according to claim 1 , wherein the polynucleotide comprises a sequence consisting of SEQ ID NO: 316 and a sequence consisting of SEQ ID NO: 318.

18. The recombinant nucleic acid molecule according to claim 1 , wherein the polynucleotide comprises a sequence consisting of SEQ ID NO: 256 and a sequence consisting of SEQ ID NO: 316.

19. The recombinant nucleic acid molecule according to claim 1 , wherein the polynucleotide comprises a sequence consisting of SEQ ID NO: 257 and a sequence consisting of SEQ ID NO: 318.

20. The recombinant nucleic acid molecule according to claim 1 , wherein the polynucleotide comprises a sequence consisting of SEQ ID NO: 256, a sequence consisting of SEQ ID NO: 257, and a sequence consisting of SEQ ID NO: 316.

21. The recombinant nucleic acid molecule according to claim 1 , wherein the polynucleotide comprises a sequence consisting of SEQ ID NO: 256, a sequence consisting of SEQ ID NO: 257, a sequence consisting of SEQ ID NO: 316, and a sequence consisting of SEQ ID NO: 318.

Assignees

• Inst Res Biomedicine
• Seattle Childrens Hospital
• Schweizerisches Tropen—Und Public Health Inst
• Schweizerisches Tropen Und Public Health Inst

Inventors

• Lanzavecchia Antonio
• Tan Joshua Hoong Yu
• Daubenberger Claudia
• Wilder Brandon

Classifications

• C07K16/205 Primary

  Plasmodium · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• A61P33/06

  Antimalarials · CPC title

• C07K2319/40

  containing a tag for immunodetection, or an epitope for immunisation · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title